Basic Information
| LncRNA/CircRNA Name | AWPPH |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, in vitro knockdown etc. |
| Sample | OS tissues and normal tissues, OS cell lines and normal cell line hFOB 1.19 |
| Expression Pattern | up-regulated |
| Function Description | AWPPH levels were increased in OS tissues in contrast to paracancerous controls. Up-regulated AWPPH was associated with advanced stage, tumor size and metastasis. Besides, AWPPH up-regulation indicated a low survival rate in OS patients. Silencing of AWPPH suppressed proliferation, migration and invasion of OS cells. Mechanistically, AWPPH was demonstrated to sponge miR-93-3p and promote FZD7 expression, causing activation of Wnt/?-catenin. Inhibition of miR-93-3p effectively reversed the effects of AWPPH knockdown on OS cells. |
| Pubmed ID | 31092328 |
| Year | 2019 |
| Title | LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/b-catenin pathway through modulating miR-93-3p/FZD7 axis |
External Links
| Links for AWPPH | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |